Jennifer Schneider
Director · VERTEX PHARMACEUTICALS INC / MA
- 2026
- May 5, 2026
- 1
Summary
Latest filing:
Jennifer Schneider is Director of VERTEX PHARMACEUTICALS INC / MA (VRTX). 1 SEC Form 4 filing on record, dated 5 May 2026.
Recent transactions
2The latest 2 SEC Form 4 transactions reported by Jennifer Schneider.
Trading pattern
InsiderAlpha's records for Jennifer Schneider go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Jennifer Schneider files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Jeffrey M. Leiden - $60.94M in VRTX purchases and sales in the last 12 months
- Amit Sachdev - $28.38M in VRTX purchases and sales in the last 12 months
- Reshma Kewalramani - $19.74M in VRTX purchases and sales in the last 12 months
- Carmen Bozic - $11.31M in VRTX purchases and sales in the last 12 months
- Charles F. Wagner Jr. - $6.38M in VRTX purchases and sales in the last 12 months
- Duncan McKechnie - $5.66M in VRTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Jennifer Schneider?
Jennifer Schneider is a corporate insider, tracked as Director of VERTEX PHARMACEUTICALS INC / MA (VRTX). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Jennifer Schneider last file a Form 4?
The only primary Form 4 on record is dated 5 May 2026.